Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489515 · ClinicalTrials.gov registry record
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
A clinical trial of Colorectal Cancer and Pancreatic Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 115
- Enrollment target
- 1
- Study location
NCT00489515: Completed study of Colorectal Cancer and Pancreatic Cancer, sponsored by Wake Forest University Health Sciences.
NCT00489515 is a study of Colorectal Cancer and Pancreatic Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 115 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00489515, a study of Colorectal Cancer and Pancreatic Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Diagnostic procedures, such as visceral lymphatic mapping using isosulfan blue, may help find cancer of the pancreas, colon, stomach, small intestine, or gallbladder and find out how far the disease has spread. PURPOSE: This clinical trial is studying the side effects and how well visceral lymphatic mapping using isosulfan blue works in patients with cancer of the pancreas, colon, stomach, small intestine, or gallbladder.
Primary Outcome
Safety will be assessed by documenting the number of adverse clinical events resulting from the procedure
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 1999-02 |
| Est. Completion | 2010-08 |
What the finished NCT00489515 record still lists
NCT00489515 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00489515 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00489515 about?
NCT00489515 is a clinical study titled "Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder". RATIONALE: Diagnostic procedures, such as visceral lymphatic mapping using isosulfan blue, may help find cancer of the pancreas, colon, stomach, small intestine, or gallbladder and find out how far the disease has spread. PURPOSE: This clinical trial is studying the side effects and how well viscer...
What is the current status of trial NCT00489515?
This trial is currently completed. The enrollment target is 115 participants. The study started on 1999-02. Estimated completion is 2010-08.
What conditions does trial NCT00489515 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Small Intestine Cancer, Gallbladder Cancer.
Who is sponsoring clinical trial NCT00489515?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00489515 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00489515's enrollment target sits among peer trials
115 206th of 381 higher than 176 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia